SCHEMBL20652980

SCHEMBL20652980

Cc1ccc(-c2nc3c(c(=O)[nH]c(=O)n3C(C)C)n2Cc2ccccc2)c(Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.53
▸ ALDH1A1 P00352 9/20 0.53
▸ MEN1 O00255 7/20 0.53
▸ KMT2A Q03164 7/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ HTT P42858 4/20 0.53
▸ MAPT P10636 4/20 0.51
▸ PKM P14618 2/20 0.51
▸ MCL1 Q07820 2/20 0.51
▸ HPGD P15428 4/20 0.50
▸ GAA P10253 1/20 0.50
▸ THRB P10828 1/20 0.49
▸ CXCL8 P10145 2/20 0.48
▸ NOD2 Q9HC29 2/20 0.48
▸ NOD1 Q9Y239 2/20 0.48
▸ TSHR P16473 2/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ BRAF P15056 1/20 0.47
▸ POLB P06746 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22105713 0.87 ALDH1A1 (0.50) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20652781 0.84 ALDH1A1 (0.54) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20652779 0.83 ALDH1A1 (0.50) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20653046 0.80 KDM4E (0.49) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL22109905 0.79 ALDH1A1 (0.51) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL22105376 0.77 TP53 (0.49) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20652972 0.76 TP53 (0.50) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20653060 0.74 ALDH1A1 (0.40) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL22105458 0.73 KDM4E (0.57) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20652982 0.73 KMT2A (0.36) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 KDM4E 3884/4885ALDH1A1 1347/4885MEN1 4272/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 KDM4E 3789/4885ALDH1A1 1488/4885MEN1 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback